{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Period+re-evaluation+of+medication",
    "query": {
      "intervention": "Period re-evaluation of medication"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 28,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Period+re-evaluation+of+medication&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-21T01:24:37.652Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04082611",
      "title": "The PREVENTION Trial: Precision Recommendations to Optimize Neurocognition",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Alzheimer Disease",
        "Mild Cognitive Impairment"
      ],
      "interventions": [
        {
          "name": "Data-Driven Clinical Recommendations",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Coached Data-Driven Clinical Recommendations",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Saint John's Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "50 Years to 80 Years"
      },
      "enrollment_count": 97,
      "start_date": "2019-07-12",
      "completion_date": "2025-04-10",
      "has_results": false,
      "last_update_posted_date": "2025-05-15",
      "last_synced_at": "2026-09-21T01:24:37.652Z",
      "location_count": 1,
      "location_summary": "Santa Monica, California",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04082611"
    },
    {
      "nct_id": "NCT02588326",
      "title": "Sensitivity of Pharmacokinetics to Differences in Particle Size Distribution of Suspension-based Nasal Sprays",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hypersensitivity"
      ],
      "interventions": [
        {
          "name": "Mometasone furoate drug formulation (MFF) 1",
          "type": "DRUG"
        },
        {
          "name": "Mometasone furoate drug formulation (MFF) 2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 80,
      "start_date": "2018-09-21",
      "completion_date": "2021-04-16",
      "has_results": false,
      "last_update_posted_date": "2021-11-16",
      "last_synced_at": "2026-09-21T01:24:37.652Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02588326"
    },
    {
      "nct_id": "NCT03169959",
      "title": "A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "2.5 mg Saxagliptin tablet",
          "type": "DRUG"
        },
        {
          "name": "5 mg dapagliflozin / 1000 mg metformin XR tablet",
          "type": "DRUG"
        },
        {
          "name": "Triple FCDP - 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR",
          "type": "DRUG"
        },
        {
          "name": "5 mg saxagliptin",
          "type": "DRUG"
        },
        {
          "name": "10 mg dapagliflozin / 1000 mg metformin XR tablet",
          "type": "DRUG"
        },
        {
          "name": "Triple FCDP - 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 85,
      "start_date": "2017-05-29",
      "completion_date": "2017-08-03",
      "has_results": false,
      "last_update_posted_date": "2017-08-14",
      "last_synced_at": "2026-09-21T01:24:37.652Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03169959"
    },
    {
      "nct_id": "NCT03410992",
      "title": "A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Plaque Psoriasis",
        "Moderate to Severe Chronic Plaque Psoriasis",
        "Psoriatic Arthritis"
      ],
      "interventions": [
        {
          "name": "Bimekizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "UCB Biopharma SRL",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 435,
      "start_date": "2018-02-05",
      "completion_date": "2020-01-07",
      "has_results": true,
      "last_update_posted_date": "2026-04-15",
      "last_synced_at": "2026-09-21T01:24:37.652Z",
      "location_count": 20,
      "location_summary": "San Diego, California • Santa Monica, California • Fort Myers, Florida + 15 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Sandy Springs",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03410992"
    },
    {
      "nct_id": "NCT04935606",
      "title": "mHealth to Enhance & Sustain Drug Use Reduction of the QUIT BI in Primary Care",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Drug Use"
      ],
      "interventions": [
        {
          "name": "Usual Care",
          "type": "BEHAVIORAL"
        },
        {
          "name": "QUIT Intervention (doctor brief advice, video doctor, health coaching sessions at 2- and 6-weeks)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "QUIT-Mobile (QUIT Intervention plus weekly mobile-web app or text message weekly self-monitoring, automated feedback over 12 months)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 457,
      "start_date": "2021-06-01",
      "completion_date": "2026-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-30",
      "last_synced_at": "2026-09-21T01:24:37.652Z",
      "location_count": 5,
      "location_summary": "Long Beach, California • Los Angeles, California",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04935606"
    },
    {
      "nct_id": "NCT02349295",
      "title": "A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Psoriatic Arthritis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Ixekizumab 80 mg Q4W",
          "type": "DRUG"
        },
        {
          "name": "Ixekizumab 80 mg Q2W",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 363,
      "start_date": "2014-12-31",
      "completion_date": "2019-06-26",
      "has_results": true,
      "last_update_posted_date": "2020-07-01",
      "last_synced_at": "2026-09-21T01:24:37.652Z",
      "location_count": 59,
      "location_summary": "Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 50 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02349295"
    },
    {
      "nct_id": "NCT04888585",
      "title": "Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rheumatoid Arthritis (RA)"
      ],
      "interventions": [
        {
          "name": "ABBV-154",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 473,
      "start_date": "2021-06-23",
      "completion_date": "2023-08-04",
      "has_results": true,
      "last_update_posted_date": "2024-10-08",
      "last_synced_at": "2026-09-21T01:24:37.652Z",
      "location_count": 101,
      "location_summary": "Phoenix, Arizona • Jonesboro, Arkansas • Fullerton, California + 89 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04888585"
    },
    {
      "nct_id": "NCT07387796",
      "title": "Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and Reinitiation",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Drug Discontinuation",
        "Substance Use Disorders",
        "Eating Behavior Changes",
        "Tirzepatide"
      ],
      "interventions": [
        {
          "name": "Discontinuation and Reinitiation of Tirzepatide",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "The University of Texas at Dallas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 40,
      "start_date": "2026-10",
      "completion_date": "2029-02",
      "has_results": false,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-09-21T01:24:37.652Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07387796"
    },
    {
      "nct_id": "NCT02660580",
      "title": "MSB11022 in Moderate to Severe Chronic Plaque Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Psoriasis",
        "Plaque Type Psoriasis",
        "Moderate to Severe Plaque Psoriasis"
      ],
      "interventions": [
        {
          "name": "MSB11022",
          "type": "DRUG"
        },
        {
          "name": "Humira®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fresenius Kabi SwissBioSim GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 443,
      "start_date": "2016-02-16",
      "completion_date": "2017-12-18",
      "has_results": true,
      "last_update_posted_date": "2023-12-27",
      "last_synced_at": "2026-09-21T01:24:37.652Z",
      "location_count": 6,
      "location_summary": "San Luis Obispo, California • Coral Gables, Florida • West Palm Beach, Florida + 2 more",
      "locations": [
        {
          "city": "San Luis Obispo",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02660580"
    },
    {
      "nct_id": "NCT05493475",
      "title": "Evaluation of a Novel Intervention to Prevent Polysubstance Overdoses Involving Illicit Stimulants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Opiate Overdose",
        "Fentanyl Overdose",
        "Harm Reduction"
      ],
      "interventions": [
        {
          "name": "Fentanyl Test Strips",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Nationwide Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 653,
      "start_date": "2022-11-10",
      "completion_date": "2025-09-29",
      "has_results": false,
      "last_update_posted_date": "2026-01-23",
      "last_synced_at": "2026-09-21T01:24:37.652Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05493475"
    }
  ]
}